Article info
PDFTherapeutics/Prevention
Randomised controlled trial
Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes
- Correspondence to: Dr Denise Campbell-Scherer, Alberta Diabetes Institute, Clinical Research Unit, 2-004 Li Ka Shing Ctr, 87 Ave and 112st, Edmonton, Alberta T6G 2E1, Canada; denise.campbell-scherer{at}ualberta.ca
Citation
Semaglutide is non-inferior to placebo for cardiovascular outcomes in patients with type 2 diabetes
Publication history
- First published March 7, 2017.
Online issue publication
March 23, 2017
Article Versions
- Previous version (7 March 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/